Pluristem Completes Enrollment of Its Multinational Phase III Study of Muscle Regeneration Following Hip Fracture Surgery
15 nov. 2021 07h10 HE
|
Pluristem Therapeutics, Inc.
Having recruited patients in the U.S., Europe and Israel, the Company anticipates topline results in the third calendar quarter of 2022 The Company will host a Key Opinion Leader online event...
Pluristem Receives Approval for Grant from the Israel Innovation Authority to Develop its Next-Generation CRISPR PLX Platform
10 nov. 2021 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading biotechnology company, today announced that it has received approval for an...
Pluristem CEO Issues Shareholder Update
22 sept. 2021 08h15 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief...
Pluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to Join its Board of Directors
19 juil. 2021 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, July 19, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today announced the Board of Director appointments of Prof....
Pluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical Readout
08 juil. 2021 07h10 HE
|
Pluristem Therapeutics, Inc.
The company will analyze data based on patients enrolled to date in COVID-19 Phase II studies in U.S., Europe and IsraelTopline results are expected during the fourth quarter of 2021 HAIFA, Israel,...
Pluristem to Receive €20M Non-Dilutive Funding from the European Investment Bank
25 mai 2021 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, May 25, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company, today announced the receipt of a “Disbursement...
Pluristem reports positive topline Phase I results in innovative hematology program, which is first to study PLX-R18 in humans
29 avr. 2021 07h00 HE
|
Pluristem Therapeutics, Inc.
New therapy has potential to generate improved blood counts in all three blood cell lineages, a meaningful advantage over existing treatmentsThe company will conduct an analyst and investor call on...
Pluristem Therapeutics Inc. Announces $30 Million Registered Direct Offering
02 févr. 2021 08h30 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
Pluristem Announces Uplisting to the Nasdaq Global Market®
27 janv. 2021 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
Pluristem Announces Appointments of Two Directors to Board
06 janv. 2021 07h00 HE
|
Pluristem Therapeutics, Inc.
HAIFA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...